These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 18524997)

  • 61. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial.
    Mannacio VA; Iorio D; De Amicis V; Di Lello F; Musumeci F
    J Thorac Cardiovasc Surg; 2008 Dec; 136(6):1541-8. PubMed ID: 19114204
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A comprehensive comparative study on the characteristics of colorectal cancer chemotherapy.
    Inoue Y; Toiyama Y; Tanaka K; Miki C; Kusunoki M
    Jpn J Clin Oncol; 2009 Jun; 39(6):367-75. PubMed ID: 19395468
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The International Conference on Harmonization common technical document--global submission format?
    Molzon JA
    Food Drug Law J; 2005; 60(3):447-51. PubMed ID: 16304749
    [No Abstract]   [Full Text] [Related]  

  • 65. [Great risks of undertreatment. Two of three hospitalized children are not receiving approved drug treatment].
    Orn P
    Lakartidningen; 2000 Feb; 97(7):685-7. PubMed ID: 10740374
    [No Abstract]   [Full Text] [Related]  

  • 66. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
    Tanaka M; Nagata T
    Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
    [TBL] [Abstract][Full Text] [Related]  

  • 67. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for use in the International Conference on Harmonisation Regions; Annex 4C on Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15992-3. PubMed ID: 19507323
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Overview of the clinical application of regenerative medicine products in Japan.
    Tsubouchi M; Matsui S; Banno Y; Kurokawa K; Kawakami K
    Health Policy; 2008 Oct; 88(1):62-72. PubMed ID: 18395290
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Current trends in the introduction of new drugs.
    De Haen P
    Clin Pharmacol Ther; 1974 Sep; 16(3):413-23. PubMed ID: 4153309
    [No Abstract]   [Full Text] [Related]  

  • 70. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparisons of Usual Dose of Pharmaceutical Products Used in Japan and United States: Can Differences Be Explained by Pharmacokinetics Alone?
    Takayanagi R; Endo Y; Kimura K; Yamada Y
    Ther Innov Regul Sci; 2019 Sep; 53(5):684-690. PubMed ID: 30380917
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Orphan drug development across Europe: bottlenecks and opportunities.
    Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
    Drug Discov Today; 2008 Aug; 13(15-16):670-6. PubMed ID: 18583178
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pediatric Drug Development in Japan: A Comparison of the Current Situation and Characteristics Between Japan and Europe.
    Ueyama E; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2020 Sep; 54(5):1152-1158. PubMed ID: 32865796
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020.
    Vokinger KN; Serra-Burriel M; Glaus CEG; Rohr UP; Hwang TJ; Dalla Torre di Sanguinetto S; Kesselheim AS
    Ann Intern Med; 2023 Oct; 176(10):1413-1418. PubMed ID: 37844306
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The overdose of drugs in Japan.
    Fukushima M
    Nature; 1989 Dec 21-28; 342(6252):850-1. PubMed ID: 2594079
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmaceutical Portfolio & Product Life Cycle Management--SMi's fourth annual conference. 29-30 June 2009, London, UK.
    Beecher N
    IDrugs; 2009 Sep; 12(9):558-60. PubMed ID: 19697274
    [No Abstract]   [Full Text] [Related]  

  • 77. Rethinking the role of older workers: promoting older worker employment in Europe and Japan.
    Rix SE
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2005 Oct; (IB77):1-32. PubMed ID: 16220615
    [No Abstract]   [Full Text] [Related]  

  • 78. [By JUPITER! Disease mongering!].
    Welin L; Peterson M
    Lakartidningen; 2008 Dec; 105(51-52):3756; discussion 3756-7. PubMed ID: 19278103
    [No Abstract]   [Full Text] [Related]  

  • 79. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
    [TBL] [Abstract][Full Text] [Related]  

  • 80. On selecting a body surface mapping procedure.
    Hoekema R; Uijen GJ; van Oosterom A
    J Electrocardiol; 1999 Apr; 32(2):93-101. PubMed ID: 10338028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.